REVIEW Nilvadipine is a racemic dihydropyridine calcium channel blocker for the treatment of hypertension and chronic major cerebral artery occlusion. It inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Sato, Yoshinari 2-Methyldihydropyridine derivatives and pharmaceutical composition containing it Ger. Offen. (1980), DE 2940833 A1 19800430.
Satu, Yoshinari 1,4-Dihydropyridine derivatives, and their pharmaceutical use U.S. (1981), US 4284634 A 19810818.
Satoh, Yoshinari; Ichihashi, Masaharu; Okumura, Kazuo Studies on nilvadipine. I. Synthesis and structure-activity relationships of 1,4-dihydropyridines containing novel substituents at the 2-position Chemical & Pharmaceutical Bulletin (1991), 39(12), 3189-201.
Honerjäger P, Seibel K, Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist. J Cardiovasc Pharmacol. 1992;20 Suppl 6:S15-21.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. CATEGORIES APIs and Bioactives > Calcium Channel Blockers